ERBB2 and neoplasm: Based on the known efficacy, safety, and pharmacokinetic similarities of H IV across eBC and mBC and the consistent role of HER2 overexpression in driving tumor growth across the HER2 spectrum, the consistent results from MetaPHER of H SC in mBC and in combination with a P-based regimen were not surprising.